Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Campieri

Showing results (121-130 of 149) with videos related to

Pageof 15
Sort By:
Inflammatory Bowel Diseases|August 23, 2001
Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitisP G Farup, T A Hinterleitner, M Lukás, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2010
Potential role of the cannabinoid receptor CB in the pathogenesis of erosive and non-erosive gastro-oesophageal reflux diseaseC Calabrese, E Spisni, G Liguori, et al.
Alimentary Pharmacology & Therapeutics|February 27, 2008
Short-term treatment with infliximab in chronic refractory pouchitis and ileitisC Calabrese, P Gionchetti, F Rizzello, et al.
Diseases of the Colon and Rectum|February 1, 1986
Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitisM Campieri, G A Lanfranchi, C Brignola, et al.
Neurogastroenterology and Motility|June 1, 2017
Stress and brain functional changes in patients with Crohn's disease: A functional magnetic resonance imaging studyA Agostini, D Ballotta, S Righi, et al.
Cancer Research|February 15, 1990
Rectal cell proliferation and colon cancer risk in ulcerative colitisG Biasco, G M Paganelli, M Miglioli, et al.
British Journal of Cancer|August 19, 2010
Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cellsA Strillacci, C Griffoni, G Lazzarini, et al.
International Journal of Colorectal Disease|November 30, 2002
The effect of transient intestinal ischemia on inflammatory parametersK M Lammers, G Innocenti, A Venturi, et al.
Alimentary Pharmacology & Therapeutics|August 19, 2011
Distinct proteomic profiles characterise non-erosive from erosive reflux diseaseC Calabrese, V Marzano, A Urbani, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2001
Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre studyM Vecchi, G Meucci, P Gionchetti, et al.
Pageof 15

Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Inflammatory Bowel Diseases|August 23, 2001
Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitisP G Farup, T A Hinterleitner, M Lukás, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2010
Potential role of the cannabinoid receptor CB in the pathogenesis of erosive and non-erosive gastro-oesophageal reflux diseaseC Calabrese, E Spisni, G Liguori, et al.
Alimentary Pharmacology & Therapeutics|February 27, 2008
Short-term treatment with infliximab in chronic refractory pouchitis and ileitisC Calabrese, P Gionchetti, F Rizzello, et al.
Diseases of the Colon and Rectum|February 1, 1986
Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitisM Campieri, G A Lanfranchi, C Brignola, et al.
Neurogastroenterology and Motility|June 1, 2017
Stress and brain functional changes in patients with Crohn's disease: A functional magnetic resonance imaging studyA Agostini, D Ballotta, S Righi, et al.
Cancer Research|February 15, 1990
Rectal cell proliferation and colon cancer risk in ulcerative colitisG Biasco, G M Paganelli, M Miglioli, et al.
British Journal of Cancer|August 19, 2010
Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cellsA Strillacci, C Griffoni, G Lazzarini, et al.
International Journal of Colorectal Disease|November 30, 2002
The effect of transient intestinal ischemia on inflammatory parametersK M Lammers, G Innocenti, A Venturi, et al.
Alimentary Pharmacology & Therapeutics|August 19, 2011
Distinct proteomic profiles characterise non-erosive from erosive reflux diseaseC Calabrese, V Marzano, A Urbani, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2001
Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre studyM Vecchi, G Meucci, P Gionchetti, et al.
Pageof 15